Daniel C. Beachler, PhD, MHS, FISPE, Staff Vice President, Safety and Epidemiology, Carelon Research
Advertisement
Articles by Daniel C. Beachler, PhD, MHS, FISPE, Staff Vice President, Safety and Epidemiology, Carelon Research
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Sanofi Eyes Insmed in Potential $43B Deal as Dupixent Patent Clock Ticks
2
How Pharma Organizations Can Scale AI Agents and Stay Audit-Ready
3
Innogen Licenses GLP-1 Therapy Efsubaglutide Alfa to Arcera
4
FDA Approves Livsayis, Regeneron's First siRNA Therapy for Myasthenia Gravis
5
